Table 4. Clinico-pathological, immunohistochemical and molecular features of trastuzumab untreated breast cancer patients (Kaplan–Meier; log-rank test).
| DFS | P | OS | P | |
|---|---|---|---|---|
| Age <50 vs ⩾50 years |
86% vs 73% |
0.061 |
89% vs 82% |
0.148 |
| Size <2 vs >2 cm |
85% vs 71% |
0.049 |
90% vs 79% |
0.095 |
| Grade (1+2 vs 3) |
84% vs 72% |
NS |
89.5% vs 80.6% |
NS |
| LVI (−) vs (+) |
76% vs 82% |
NS |
83% vs 91% |
NS |
| LN (−) vs (+) |
83% vs 69% |
0.021 |
88% vs 79% |
0.102 |
| Stage (I+II vs III) |
81% vs 61% |
0.004 |
88% vs 67% |
0.001 |
| CNS mets |
0% vs 0% |
NS |
40% vs 0% |
NS |
| Liver mets |
0% vs 0% |
NS |
33% vs 33% |
NS |
| Lung mets |
0% vs 0% |
NS |
50% vs 0% |
0.039 |
| ER (−) vs (+) |
67% vs 83% |
0.067 |
79% vs 87% |
NS |
|
α-IGF1R |
76% vs 82% |
NS |
83% vs 89% |
NS |
| EGFR |
80% vs 57% |
0.003 |
87% vs 71% |
0.016 |
| PTEN loss |
72% vs 96% |
NS |
83% vs 100% |
NS |
|
PI3KCA mutations |
77% vs 77% |
NS |
83.5% vs 90.5% |
NS |
| p110α |
100% vs 75% |
NS |
100% vs 83% |
NS |
| pAkt |
74% vs 79% |
NS |
74% vs 88% |
NS |
| p-mTOR |
73% vs 82% |
NS |
82% vs 89% |
NS |
| pMAPK |
78% vs 78% |
NS |
78% vs 86% |
NS |
| p27 |
75% vs 79.5% |
NS |
85% vs 82% |
NS |
| pSrc-Y416 | 76% vs 80% | NS | 84% vs 85% | NS |
Abbreviations: CNS=central nervous system; EGFR=epidermal growth factor receptor; ER=oestrogen receptor; IGF1R=insulin-like growth factor 1-receptor; LN=lymph nodes; LVI=lymph vascular invasion; mets=metastasis.